Breaking Boundaries: Immunotherapy for Myeloid Malignancies.

Cancers (Basel) · 2024 · PMC11352449 · PMID 39199554

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

An initial phase 3 study of patients with ND-AML receiving daunorubicin and cytarabine (DA) with or without GO at a dose of 6 mg/m 2 on day 4 showed a trend toward superior survival in the DA-only group.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.